

Media Release

Zug, 26 June 2017

Shareholders' Meeting approved all proposals by the Board of Directors

At today's ordinary Shareholder's Meeting of HBM Healthcare Investments Ltd the Shareholders approved all of the proposals submitted by the Board of Directors. A total of about 47% of all shares were represented at the Shareholders' Meeting.

Along with the reduction of the share capital by means of the cancellation of 260'000 registered shares, the Shareholders also approved a withholding tax-exempt distribution from the reserve from capital brought in of CHF 5.80 per share. The cash payment to shareholders will be made on 30 June 2017. Until 27 June 2017, the shares will be traded with entitlement for the cash distribution (as from 28 June 2017 without such entitlement, ex-date).

After the registration of the reduction of share capital in the commercial register, which is expected to take place early in September 2017, the share capital of HBM Healthcare Investments Ltd will amount to CHF 411,84 million, divided into 7,04 million registered shares with a par value of CHF 58.50 each.

Further, the Shareholders approved the amendment of the articles of association according to the motion of the Board of Directors.

The Chairman of the Board of Directors, the Members of the Board of Directors as well as the Members of the Compensation Committee were all re-elected for a further term of one year. The Shareholders also approved the proposed compensation to the Board of Directors and to the Management.

The presentation shown at the Shareholders' Meeting is available on our website www.hbmhealthcare.com.

For further information, please contact Dr Andreas Wicki, tel.: +41 41 710 75 77, andreas.wicki@hbmhealthcare.com.

NOT FOR DISTRIBUTION IN THE USA, CANADA, JAPAN OR AUSTRALIA

HBM Healthcare Investments

Information on HBM Healthcare Investments Ltd

HBM Healthcare Investments actively invests in the human medicine, biotechnology, medical technology and diagnostics sectors and related areas. The company holds and manages an international portfolio of promising companies. Many of these companies have their lead products already available on the market or at an advanced stage of development. The portfolio companies are closely tracked and actively guided on their strategic directions. This is what makes HBM Healthcare Investments an interesting alternative to investing in big pharma and biotech companies. HBM Healthcare Investments has an international shareholder base and is listed on SIX Swiss Exchange (ticker: HBMN).

Disclaimer

This media release does not constitute an issue prospectus within the meaning of Art. 652a or Art. 1156 of the Swiss Code of Obligations, a listing prospectus in the sense of the SIX Swiss Exchange Listing Rules or a securities prospectus as defined in the German Securities Prospectus Act (*Wertpapierprospektgesetz*). Publication is for information purposes only and constitutes neither an offer to sell nor an invitation to buy or subscribe for securities. This media release and the information it contains must not be distributed or forwarded to or within the United States of America (USA) or to US persons (including legal entities) or publications with a general circulation in the USA. This media release does not constitute an offer or invitation to purchase any securities in the USA. The securities of HBM Healthcare Investments Ltd have not been registered under United States securities legislation and may not be offered, sold or delivered within the USA or to US persons without prior registration or the corresponding exemption from the registration requirements of US securities legislation.

HBM Healthcare Investments Ltd

Bundesplatz 1, P.O. BOX 1145, CH-6300 Zug | Tel: +41 41 710 75 77 | Fax: +41 41 710 75 78 | info@hbmhealthcare.com
www.hbmhealthcare.com